|PRX-003 is an anti-MCAM mAb developed as a novel therapy for psoriasis. In patients with autoimmune diseases, a subset of MCAM+ve T cells (which have an effector memory T-helper 17 phenotype) produce high levels of pro-inflammatory IL-17 [1,3]. Pharmacological disruption of MCAM function is thought to be a valid mechanism for the treatment of autoimmune inflammation. Peptide sequence alignments identify PRX-003 as one of the preferred antibodies claimed in patent WO2014039975  (SEQ IDs 119 and 123 match the sequences submitted to the WHO for INN imaprelimab). These peptide sequences map to the construct identified as h2120VH5/L3.